Login to Your Account

Nektar Cashes in Cimzia, Mircera Royalties for $124M

By Mari Serebrov
Washington Editor

Thursday, March 1, 2012

Rather than banking on its future royalties of Cimzia and Mircera, Nektar Therapeutics Inc. cashed them in for $124 million to pay down its $215 million convertible debt that comes due in September.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription